McKesson Buy Rating Reiterated as Precision Medicine Acquisition Strengthens Oncology Platform; $1050 Price Target Unchanged
Tip Ranks·- Bank of America Securities analyst Allen Lutz reaffirmed a buy rating on McKesson with an unchanged price target of $ 1050 on August 18. - The rating is supported by McKesson's strategic acquisition of Precision Medicine Group, which enhances its oncology platform and early drug development capabilities. - Barclays also maintained a buy rating on the stock with a price target of $ 1000.00 in a separate report issued on the same day.